伊马替尼治疗前接受羟基脲治疗并获得主要分子反应（MMR）的 CML 患者与未获得主要分子反应的患者的 HIF2-α 表达比较

{"title":"伊马替尼治疗前接受羟基脲治疗并获得主要分子反应（MMR）的 CML 患者与未获得主要分子反应的患者的 HIF2-α 表达比较","authors":"I. Rinaldi, Radinal Mauludi, Sri Jusman, R. Sinto, K. Harimurti","doi":"10.2147/jbm.s436015","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":506923,"journal":{"name":"Journal of Blood Medicine","volume":"40 14","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR\",\"authors\":\"I. Rinaldi, Radinal Mauludi, Sri Jusman, R. Sinto, K. Harimurti\",\"doi\":\"10.2147/jbm.s436015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":506923,\"journal\":{\"name\":\"Journal of Blood Medicine\",\"volume\":\"40 14\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Blood Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/jbm.s436015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/jbm.s436015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}